Last reviewed · How we verify
NCT05739409
LILRB4 STAR-T Cell Therapy for Monocytic Leukemia
NA trial testing LILRB4 STAR-T cells injection in Acute Myelogenous Leukemia in 1 participant. Completed in 9 May 2023.
9 May 2023
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1 |
| Start date | 16 February 2023 |
| Primary completion | 9 May 2023 |
| Estimated completion | 9 May 2023 |
| Sites | 2 locations across China |
Drugs / interventions tested
- LILRB4 STAR-T cells injection — full drug profile →
Conditions studied
- Acute Myelogenous Leukemia — all drugs for Acute Myelogenous Leukemia →
- Chronic Myelomonocytic Leukemia — all drugs for Chronic Myelomonocytic Leukemia →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
Adults 18 to 70, any sex, with Acute Myelogenous Leukemia or Chronic Myelomonocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center,single-arm,open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in Monocytic Leukemia subjects.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Human leukocyte immunoglobulin-like receptors in health and disease.
Redondo-García S, Barritt C, Papagregoriou C, Yeboah M, et al · · 2023 · cited 34× · PMID 38022598 · DOI 10.3389/fimmu.2023.1282874 -
The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications.
Hodges A, Dubuque R, Chen SH, Pan PY. · · 2024 · cited 9× · PMID 39696628 · DOI 10.1186/s40364-024-00705-7 -
Leukocyte immunoglobulin-like receptor B4 (LILRB4) in acute myeloid leukemia: From prognostic biomarker to immunotherapeutic target.
Li M, Zhao X. · · 2024 · cited 5× · PMID 38973293 · DOI 10.1097/cm9.0000000000003195 -
Inhibitory leukocyte immunoglobulin-like receptors, subfamily B (LILRBs) in human diseases: structure, roles, mechanisms, and clinical applications.
Zhang Y, Xu Y, Wu Q, Fu X, et al · · 2025 · cited 1× · PMID 40860159 · DOI 10.7150/thno.116951
Verify or expand the search:
- PubMed search for NCT05739409
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myelogenous Leukemia
Currently open trials in the same condition.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
- NCT06680661 — ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis · Phase 2 · recruiting
- NCT06131801 — Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · recruiting
- NCT05974150 — Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia · recruiting
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05739409 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 11 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05739409.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing